Literature DB >> 12665799

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.

Barbara Picconi1, Diego Centonze, Kerstin Håkansson, Giorgio Bernardi, Paul Greengard, Gilberto Fisone, M Angela Cenci, Paolo Calabresi.   

Abstract

Long-term treatment with the dopamine precursor levodopa (L-DOPA) induces dyskinesia in Parkinson's disease (PD) patients. We divided hemiparkinsonian rats treated chronically with L-DOPA into two groups: one showed motor improvement without dyskinesia, and the other developed debilitating dyskinesias in response to the treatment. We then compared the plasticity of corticostriatal synapses between the two groups. High-frequency stimulation of cortical afferents induced long-term potentiation (LTP) of corticostriatal synapses in both groups of animals. Control and non-dyskinetic rats showed synaptic depotentiation in response to subsequent low-frequency synaptic stimulation, but dyskinetic rats did not. The depotentiation seen in both L-DOPA-treated non-dyskinetic rats and intact controls was prevented by activation of the D1 subclass of dopamine receptors or inhibition of protein phosphatases. The striata of dyskinetic rats contained abnormally high levels of phospho[Thr34]-DARPP-32, an inhibitor of protein phosphatase 1. These results indicate that abnormal information storage in corticostriatal synapses is linked with the development of L-DOPA-induced dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665799     DOI: 10.1038/nn1040

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  232 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.

Authors:  Xuebing Cao; Toru Yasuda; Subramaniam Uthayathas; Ray L Watts; M Maral Mouradian; Hideki Mochizuki; Stella M Papa
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 3.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

4.  Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.

Authors:  Tanya Chotibut; Samantha Meadows; Ella A Kasanga; Tamara McInnis; Mark A Cantu; Christopher Bishop; Michael F Salvatore
Journal:  Mov Disord       Date:  2017-06-20       Impact factor: 10.338

5.  Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy.

Authors:  Jill R Crittenden; Ippolita Cantuti-Castelvetri; Esen Saka; Christine E Keller-McGandy; Ledia F Hernandez; Lauren R Kett; Anne B Young; David G Standaert; Ann M Graybiel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

6.  A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.

Authors:  Allison E Girasole; Matthew Y Lum; Diane Nathaniel; Chloe J Bair-Marshall; Casey J Guenthner; Liqun Luo; Anatol C Kreitzer; Alexandra B Nelson
Journal:  Neuron       Date:  2018-02-01       Impact factor: 17.173

7.  Cyclic AMP and afferent activity govern bidirectional synaptic plasticity in striatopallidal neurons.

Authors:  Shana M Augustin; Jeff A Beeler; Daniel S McGehee; Xiaoxi Zhuang
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

8.  Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

Authors:  Nikhil M Urs; Simone Bido; Sean M Peterson; Tanya L Daigle; Caroline E Bass; Raul R Gainetdinov; Erwan Bezard; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 9.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

10.  Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice.

Authors:  Lisa Won; Yunmin Ding; Pardeep Singh; Un Jung Kang
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.